Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells

• Published in: Molecular cancer therapeutics Vol. 3; no. 6; pp. 661 - 669
• Main Authors: Lee, Eric A, Keutmann, Michael K, Dowling, Melissa L, Harris, Eleanor, Chan, Gordon, Kao, Gary D
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 01.06.2004
• Subjects: Antineoplastic Agents, Phytogenic - pharmacology; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; CDC2 Protein Kinase - antagonists & inhibitors; CDC2 Protein Kinase - metabolism; Cell Cycle Proteins - metabolism; Cell Death - drug effects; Cell Survival - drug effects; Drug Resistance, Neoplasm; Female; Humans; Interphase - drug effects; Microtubules - drug effects; Mitosis - drug effects; Mitosis - physiology; Nocodazole - pharmacology; Organ Specificity; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - metabolism; Ovarian Neoplasms - pathology; Paclitaxel - pharmacology; Protein Kinases - metabolism; Protein-Serine-Threonine Kinases; Tumor Cells, Cultured

Drugs that disrupt microtubule dynamics include some of the most important of cancer chemotherapies. While these drugs, which include paclitaxel (Taxol), are known to invoke the mitotic checkpoint, the factors that determine cancer cell killing remain incompletely characterized. Cells that are relat...